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Abstract
Background: Most available drugs against visceral leishmaniasis are toxic, and growing limitations in available
chemotherapeutic strategies due to emerging resistant strains and lack of an effective vaccine against visceral leishmaniasis
deepens the crisis. Antineoplastic drugs like miltefosine have in the past been effective against the parasitic infections. An
antineoplastic drug, cisplatin (cis-diamminedichloroplatinum II; CDDP), is recognized as a DNA-damaging drug which also
induces alteration of cell-cycle in both promastigotes and amastigotes leading to cell death. First in vivo reports from our
laboratory revealed the leishmanicidal potential of cisplatin. However, high doses of cisplatin produce impairment of kidney,
which can be reduced by the administration of antioxidants.
Methodology/Principal Findings: The present study was designed to evaluate the antileishmanial effect of cisplatin at
higher doses (5 mg and 2.5 mg/kg body weight) and its combination with different antioxidants (vitamin C, vitamin E and
silibinin) so as to eliminate the parasite completely and reduce the toxicity. In addition, various immunological,
hematological and biochemical changes induced by it in uninfected and Leishmania donovani infected BALB/c mice were
investigated.
Conclusion/Significance: A significant reduction in parasite load, higher IgG2a and lower IgG1 levels, enhanced DTH
responses, and greater concentration of Th1 cytokines (IFN-c, IL-2) with a concomitant down regulation of IL-10 and IL-4
pointed towards the generation of the protective Th1 type of immune response. A combination of cisplatin with
antioxidants resulted in successful reduction of nephrotoxicity by normalizing the enzymatic levels of various liver and
kidney function tests. Reduction in parasite load, increase in Th1 type of immune responses, and normalization of various
biochemical parameters occurred in animals treated with cisplatin in combination with various antioxidants as compared to
those treated with the drug only. The above results are promising as antioxidants reduced the potential toxicity of high
doses of cisplatin, making the combination a potential anti-leishmanial therapy, especially in resistant cases.
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Introduction
Pentavalent antimonial compounds like sodium stibogluconate
and N-methylglucamine antimoniate have been the mainstay of
antileishmanial therapy [1]. They remain the conventional
treatment of children and adults all over the world except in
Bihar (India) where Sb is no longer useful owing to high failure
rates due to resistance [2,3] and also have the disadvantage of
toxicity, parenteral administration and need for long duration of
therapy [4]. Secondary treatment regimens with amphotericin B
and pentamidine are effective but these are also parenteral, have
to be administered for prolonged periods and therefore, are
expensive and potentially toxic [2]. Liposomal formulations of
amphotericin B target the cells that host the parasite and have
decreased nephrotoxicity but are prohibitively costly. Paromomy-
cin have advantages of high level of efficacy and low rates of
adverse reaction, but the drawback is its high cost [5]. Oral drugs
sitamaquine (WR 6020) and miltefosine are the two promising oral
antileishmanial compounds. Miltefosine (hexadecylphosphocho-
line) is a membrane activating alkyl phospholipid, having cure
rates of approximately 90–95%. It has an obvious advantage in
being an active oral agent and hospitalization is thus not required
[3] but is teratogenic in animals [3] so cannot be used in pregnant
women. Considering the fact that therapeutic interventions against
visceral leishmaniasis (VL) are limited and facing serious concerns
of toxicity, high cost and emerging resistance, there is a greater
interest in new drug developments which are cost effective,
efficient and easily available to people suffering from leishmaniasis.
An antineoplastic drug, cisplatin (cis-diamminedichloroplati-
num II; CDDP) a platinum-containing compound, is recognized
as a DNA-damaging drug [6] and is known to augment the
cytotoxic T-lymphocyte mediated antitumor immunity [7,8]. It
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concentration of 0.25–64 mM and has been shown to lead towards
an apoptosis like cell death of both promastigotes and amastigotes
[9]. First in vivo report from our laboratory also showed a
significant reduction in parasite load and enhanced DTH
responses which suggested the generation of the cell-mediated
immune responses. Though the protective efficacy of the drug [10]
was demonstrated, it could not completely eliminate the parasite at
low dosages of 0.5 and 1 mg/kg b.wt.
In spite of its good antineoplastic activity against various cancer
treatments, its clinical use was rapidly limited due to unexpected
and very severe renal toxicity [11]. The kidney selectively
accumulates cisplatin and its analogues to a higher degree than
other organs, probably through mediated transport [12]. Cisplatin
treatment also induces extensive death of cells in the proximal and
distal tubules and loop of Henle [13]. High doses of cisplatin
produce impairment of kidney and are recognized as the most
important dose limiting factor [14]. Mild nephrotoxicty has also
been reported with the cisplatin at a dose of 1 mg/kg body wt.
[10]. Nephrotoxicity of cisplatin has been reported to be reduced
by the administration of antioxidants [15,16]. At higher doses,
cisplatin may be used in combination with antioxidants which
might suppress the drug-induced toxic effects, and may help in
complete elimination of the parasite from the host reticulo-
endothelial system. All these factors led to designing of the present
study where we attempted to test the leishmanicidal activity of
cisplatin at high dosages of 2.5 and 5 mg/kg b.wt. Since, cisplatin
causes nephrotoxicity at higher dosages, we have studied the
nephroprotective potential of different antioxidants i.e. vitamin C,
vitamin E and silibinin.
Methods
Parasite and culture conditions
Leishmania donovani promastigotes of strain MHOM/IN/80/
Dd8, originally obtained from the London School of Hygiene and
Tropical Medicine, London, were used for the present study and
maintained in vitro at 2261uC in modified NNN medium by serial
subcultures after every 48–72 h.
Animals
5–6 weeks old inbred BALB/c mice, weighing 20–25 g were
obtained from IMTECH and Central Animal House of Panjab
University, India. They were fed with water and mouse feed ad
libitum.
Ethics statement
Experiments were carried out according to the guidelines of the
Committee for the purpose of Control and Supervision of
Experiments on Animals (CPCSEA, Registration No. 45/1999/
CPCSEA). The ethical clearance for conducting various experi-
ments mentioned in the study on BALB/c mice was taken from
Institutional Animal Ethics Committee (IAEC) of the Panjab
University, Chandigarh in its meeting held on 25.08.2008
(Approval No. 1334-50/CAH/3.09.2008).
Drug
cis-diamminedichloroplatinum (II) dichloride (CP) was pur-
chased from Sigma Aldrich Co., USA and was dissolved in
distilled water to get the required concentration of 5 mg/kg body
weight (b.wt.) and 2.5 mg/kg body weight (b.wt.). Sodium
stibogluconate (SSG) was dissolved in distilled water in water
bath at 72uC to get the required concentration of 40 mg/kg b.wt.
Vitamin C (Ascorbic acid), vitamin E [(6)-a-Tocopherol] and
Silibinin were also purchased from Sigma Aldrich Co., USA.
Vitamin C was dissolved in distilled water, Vitamin E was
dissolved in corn oil and silibinin was dissolved in saline to get the
required concentration of 200 mg/kg b.wt of vitamin C, 100 mg/
100 g b.wt. of vitamin E and 200 mg/kg b.wt. of silibinin.
Infection and drug treatment
Infection. Inbred BALB/c mice were infected with the dose
of 10
7 promastigotes of L. donovani by intracardiac route [17].
Drug treatment. Cisplatin was administered to all groups of
animals after 30 post infection days (p.i.d.). All the groups of
animals were further divided into two groups (A and B). Group
A was treated with cisplatin at a dose of 5 mg/kg b.wt.,
intraperitoneally for 5 days [18] and group B was treated with
cisplatin at a dose of 2.5 mg/kg b.wt., intraperitoneally for 5 days
[15]. The group sizes were n=6 for each subgroup (Table 1).
Assessment of Infection. After the completion of five days
of treatment, 6 mice from each group were sacrificed after 1, 15,
30 post treatment days (p.t.d.) along with infected and normal
controls. Parasite load was assessed in the impression smears of
liver in terms of Leishman Donovan Units by the method of
Bradley and Kirkley [19].
Delayed type hypersensitivity (DTH) response. All
groups of mice were challenged in the right foot pad with a
subcutaneous injection of leishmanin. [For preparing leishmanin,
promastigotes in the stationary phase of growth were harvested
from modified NNN medium and washed thrice with PBS
(Phosphate buffer saline). The final pellet was then suspended in
5 ml of 0.5% phenol in sterile PBS and kept at room temperature
for 10 min. The phenol was then removed and the final
concentration was adjusted to 2610
8 promastigotes per ml]. After
48 hr, the thickness of the right and left foot pads were measured
using vernier calliper. The percentage increase in the thickness of
the right foot pad as compared to the left foot pad of mice was
calculated [20].
Assessment of antibody response. The humoral immune
response induced by the antigens was evaluated by measuring total
specific IgG by indirect ELISA from serum samples collected from
different groups of animals by using commercially available kits
(Bangalore Genei, Bangalore, India).
Author Summary
Leishmaniasis, a neglected tropical disease (NTD) caused
by Leishmania, has been put on the World Health
Organization agenda for eradication as a part of their
Special Programme for Tropical Diseases Research. Visceral
leishmaniasis (VL) is a life-threatening disease when no
treatment is given. Most of the drugs still used to treat VL
are often expensive, difficult to administer, have serious
side effects, and several are becoming ineffective because
of increasing parasite resistance. Cisplatin is a first-
generation platinum-containing drug, used in the treat-
ment of various solid tumors. We have for the first time
characterized the in vivo effect of cisplatin in murine
experimental visceral leishmaniasis, but at higher doses it
is nephrotoxic. Considering the above findings, the
present study was designed to evaluate the protective
efficacy of the drug in combination with various antiox-
idants to reduce or prevent cisplatin-induced nephrotox-
icity. Drug treatment induces a higher secretion of Th1
cytokines, diminution in parasite burden, and the supple-
mentation of antioxidants which are antagonists of the
toxicity helps in reducing the nephrotoxicity.
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specific serum immunoglobulin G (IgG) isotype antibody response
was measured by conventional ELISA [20] by using commercially
available kits (Bangalore Genei, Bangalore, India).
Determination of drug-induced cytokine production. The
lymphocytes from spleens of infected and drug treated mice of
different groups were cultured in 24 well plates in RPMI-1640
medium containing 20 mM NaHCO3,1 0m MH E P E S ,1 0U / m lo f
penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 10%
FCS. Cells were stimulated with 50 mg/ml of the crude antigen and
incubated at 37uC for 72 h and supernatant of all cultures was
collected and stored at 220uC till further use. These were
subsequently used for the determination of cytokine levels using
commercially available kits from Bender Med Systems, Austria (IL-4
and IL-10) and Diaclone, France (IFN-c and IL-2) according to
manufacturer’s instructions.
Evaluation of hematological parameters. Hemoglobin
(Hb) estimation was done by Sahli’s hemometer (Marienfeld
Lab. Glassware, Germany) and total leukocyte count (TLC)
estimation was done by the method of Khynriam and Prasad [21].
Evaluation of biochemical parameters
Liver Function Tests. The estimation of Alkaline phosphatase
(ALP), Acid phosphatase (ACP), Lactate dehydrogenase (LDH),
Serum Glutamate Oxaloacetate Transaminase (SGOT), Serum
Glutamate Pyruvate Transaminase (SGPT) was done in serum
samples by using commercially available kits (Reckon Diagnostics
Pvt. Ltd Baroda, India; Span Diagnostic Ltd. and Kinetik Koncepts,
Gurgaon, India).).
Kidney Function Tests. The estimation of Urea, blood urea
nitrogen (BUN), Creatinine, Uric acid and the electrolytes like
Na
+,K
+,M g
++,C l
2,C a
++ and PO4 was done in serum samples
using commercially available kits (Reckon Diagnostics Pvt. Ltd
Baroda, India; Transasia Bio-medical Ltd. India; Coral Clinical
Systems, Goa, India and M/S Excel Diagnostics Pvt. Ltd. India).
Mortality rate. Mortality rate was calculated in order to
estimate the overall mortality among different group of animals.
Statistical analysis. All the experiments were performed
three times independently. All data comparisons were tested for
significance by using one-way ANOVA; P values of ,0.05 and
,0.001 were considered significant. Results were expressed as
mean6S.D. of one of three independent experiments.
Results
Hepatic parasite load
Mice treated with cisplatin showed significant reduction in the
parasite load as compared to infected untreated controls. Cisplatin
at the dosage of 5 mg/kg b.wt. showed significantly lesser parasite
burden as compared to those treated with 2.5 mg/kg b.wt. of
cisplatin. The reduction in parasite burden in cisplatin treated
groups was observed to be 97% (5 mg/kg b.wt.) and 91% (2.5 mg/
kg b.wt.) on 30 p.t.d. The percent decrease in parasite load was
found to be in the range of 84–97% in animals treated with cisplatin
along with different antioxidants. Similar trend was observed in
mice treated with 2.5 mg/kg b.wt. of cisplatin. Results were also
comparable with the group of infected animals treated with SSG
(positive control), where reduction in parasite burden was found to
be in the range of 84–97% on 1, 15 and 30 p.t.d. (Fig. 1).
Delayed type hypersensitivity response
A profound delayed type hypersensitivity response was induced
by cisplatin treated L. donovani infected animals, suggesting the
generation of cell-mediated immune responses. The percentage
increase in footpad thickness in the infected animals treated with
5 mg/kg b.wt. of cisplatin was found to be significantly higher than
those treated with 2.5 mg/kg b.wt. of the drug. In infected animals
where antioxidants were given along with cisplatin at the dosage of
5 mg/kg b.wt., the DTH response was significantly increased from
1 to 30 p.t.d. The increase in DTH response varies from 28–46% in
animalstreated with cisplatinalong with antioxidants. Furthermore,
treatment with cisplatin (2.5 mg/kg bwt.) in combination with
different antioxidants, significantly increased the DTH response on
30 p.t.d. as compared to infected controls. When cisplatin treated
animals were compared with SSG treated animals then the increase
was found to be comparable (Fig. 2).
Assessment of antibody response
The IgG levels were found to be highest in the infected
untreated controls as compared to the infected cisplatin treated
animals. With increase in post treatment days, the IgG antibody
response in infected mice treated with cisplatin (5 mg/kg b.wt. and
2.5 mg/kg b.wt.) was observed to be significantly lower as
compared to control animals and the maximum antibody response
was produced in infected untreated animals. IgG levels in the
infected animals treated with 5 mg/kg b.wt. of cisplatin were
found to be significantly lower than those treated with 2.5 mg/kg
b.wt. of the drug. When cisplatin treated animals were compared
with SSG treated animals then the decrease in antibody titre was
found to be comparable (Fig. 3A).
ELISA for parasite-specific IgG1 and IgG2a isotypes
IgG1 and IgG2a antibody responses were also evaluated by
ELISA using specific anti-mouse isotype antibodies. Similarly, in
addition to IgG levels, decreased IgG1 levels were found in
Table 1. Various groups used in the study.
Sr. No. Groups of animals Dosage
1 Cisplatin+Silibinin 200 mg/kg b.wt. of silibinin, given intraperitoneally.
2 Cisplatin+VitaminC+VitaminE 100 mg/100 g b.wt. of vitamin E and 200 mg/kg b.wt. of Vitamin C,
both given orally.
3 Cisplatin+Silibinin+Vitamin C+Vitamin E 200 mg/kg b.wt. of silibinin given intraperitoneally. 100 mg/100 g b.wt.
of vitamin E and 200 mg/kg b.wt. of Vitamin C, both given orally.
4 Sodium stibogluconate (SSG) (Positive control) 40 mg/kg b.wt. for 5 days
5 Infected control 10
7 promastigotes of L. donovani by intracardiac route.
6 Normal control Saline treated
doi:10.1371/journal.pntd.0001629.t001
Nephroprotective Effects of Antioxidants
www.plosntds.org 3 May 2012 | Volume 6 | Issue 5 | e1629infected cisplatin treated animals as compared to infected
untreated controls.
Treatment of infected animals with cisplatin (5 mg/kg b.wt. and
2.5 mg/kg b.wt.) significantly increased the IgG2a antibody titre
on 30 p.t.d. as compared to infected animals. Treatment of
animals with cisplatin led to a sudden increase in the IgG2a levels
on 1 p.t.d. and further decreased on 30 p.t.d. but was still higher
than infected controls. The increase was more pronounced in
infected animals treated with cisplatin at a dosage of 5 mg/kg
b.wt. as compared to infected animals treated with cisplatin at
dosage of 2.5 mg/kg b.wt. When antioxidants were supplemented
along with cisplatin at the dosage of 5 mg/kg b.wt., the IgG2a
antibody titre was found to be higher than the infected controls.
This increase in IgG2a antibody titre varies from 0.18860.003–
0.14660.003 in cisplatin+vitC+vitE+silibinin, 0.18760.005–0.1486
0.002 in cisplatin+vitC+vitE and 0.18760.0.005–0.14760.0.009 in
cisplatin+silibinin treated animals on 30 p.t.d. Similar trend was
observed in mice treated with 2.5 mg/kg bwt. of cisplatin. When
Figure 1. Parasite load in terms of LDU in different groups of animals. The data are presented as mean6S.D. of six mice per group. * -p
value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m gC P +Silibinin/Infected+5m gC P +VitE+VitC/Infected+5m gC P +VitE+VitC+Si-
libinin.* - p,0.001. No significant difference was found in groups: Infected+5 mg CP vs Infected+5m gC P +Silibinin/Infected+5m gC P +VitE+VitC/
Infected+5m g C P +VitE+VitC+Silibinin and Infected only vs Infected+Silibinin/Infected+VitE+VitC/Infected+VitE+VitC+Silibinin. LDU- Leishman
Donovan Units.
doi:10.1371/journal.pntd.0001629.g001
Figure 2. Percentage increase in footpad thickness (DTH response) in different groups of animals. The data are presented as mean6S.D.
of six mice per group. * -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m gC P +Silibinin/Infected+5m gC P +VitE+VitC/
Infected+5m gC P +VitE+VitC+Silibinin. { -p value: Infected+5 mg CP vs. Infected+5m gC P +Silibinin/Infected+5m gC P +VitE+VitC/Infected+5m g
CP+VitE+VitC+Silibinin. *,{-p,0.001.
doi:10.1371/journal.pntd.0001629.g002
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then the increase in antibody titres was found to be comparable
(Fig. 3B and 3C).
Determination of drug-induced cytokine production
The cytokine responses (IFN-c, IL-2, IL-4 and IL-10) in
supernatants of spleen cells, cultured in the presence of crude
antigen (50 mg/ml), were analyzed for different groups of animals.
Th1-specific cytokines, that is, IFN-c and IL-2 levels were
significantly greater in infected mice treated with cisplatin
(5 mg/kg b.wt. and 2.5 mg/kg b.wt.) as compared to infected
untreated animals and uninfected treated mice. The levels of IFN-
c and IL-2 decreased from 1 p.t.d. to 30 p.t.d., however they were
still higher than infected controls. The levels of these cytokines
Figure 3. Levels of Leishmania-specific IgG antibodies in serum samples of different groups of animals. A -IgG, B -IgG1 and C -IgG2a. The
data are presented as mean6S.D. of six mice per group. *,# -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m gC P +Silibinin/
Infected+5m gC P +VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. {,1 -p value: Infected+5 mg CP vs. Infected+5m gC P +Silibinin/Infected+5m g
CP+VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. *,{-p,0.001; #,1-p,0.05.
doi:10.1371/journal.pntd.0001629.g003
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with cisplatin and antioxidants treated animals. Also, when the
cisplatin treated animals were compared with SSG treated animals
then the increase in IFN-c and IL-2 levels were found to be
comparable (Fig. 4A and 4B).
The levels of Th2-regulated cytokines, IL-4 and IL-10, were
minimum in the infected animals treated with cisplatin. Spleen
cells from infected mice, however, produced much more IL-4 than
the cisplatin treated groups. This effect of cisplatin in down-
regulating IL-4 and IL-10 production was seen in almost all the
animals treated along with different antioxidants on different post
treatment days. The levels of IL-10 and IL-4 produced by
splenocytes of infected and cisplatin treated mice were comparable
to that induced by SSG treatment. (Fig. 5A and 5B).
Hematological investigations
A decrease in hemoglobin levels were observed in infected and
uninfected cisplatin (5 mg/kg b.wt. and 2.5 mg/kg b.wt.) treated
animals as compared to normal control animals. When antioxi-
dants were given along with the drug in infected animals,
hemoglobin levels were found to be in normal range of 8–10 g/
dl. Leucopenia was observed in infected and uninfected cisplatin
(5 mg/kg b.wt. and 2.5 mg/kg b.wt.) treated animals while
leucocytosis was observed in infected untreated animals. TLC
was found to be in normal range of 7000–12000/mm
3 when
antioxidants were supplemented along with cisplatin. When
compared with SSG, the results were found to be comparable
(Fig. 6A and 6B).
Liver function tests
Quantitative estimation of SGOT and SGPT activity revealed
maximum activity in infected mice treated with cisplatin followed
by uninfected cisplatin treated mice and then infected untreated
mice. Enzyme activity in mice treated with 5 mg/kg b.wt. of
cisplatin was found to be maximum in comparison to those
treated with 2.5 mg/kg b.wt. of the drug and thus showed a sharp
decline from 1 to 30 p.t.d. when antioxidants were supplemented
along with the cisplatin at the dosage of 5 mg/kg b.wt. The
percent decrease in SGOT level was found to be 96–80% in
cisplatin+vitC+vitE+silibinin, 97–82% in cisplatin+vitC+vitE and
97–93% in cisplatin+silibinin treated animals on 30 p.t.d.
(Fig. 7A).
Figure 4. Cytokine levels in culture supernatants of spleen cells of different groups of animals. A- IFN-c, B-IL-2. The data are presented as
mean6S.D. of six mice per group. * -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m g C P +Silibinin/Infected+5m g
CP+VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. { -p value: Infected+5 mg CP vs. Infected+5m gC P +Silibinin/Infected+5m gC P +VitE+VitC/
Infected+5m gC P +VitE+VitC+Silibinin. *,{-p,0.001.
doi:10.1371/journal.pntd.0001629.g004
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cisplatin+vitC+vitE+silibinin, 93–90% in cisplatin+vitC+vitE and
91.86–91.98% in cisplatin+silibinin treated animals on 30 p.t.d. as
compared to infected cisplatin treated mice (Fig. 7B).
Similarly, SGOT and SGPT levels were found to be
significantly reduced when antioxidants were given with cisplatin
at the dosage of 2.5 mg/kg bwt. When compared with SSG, the
results were found to be comparable.
The alkaline phosphatase and acid phosphatase activity was
found to be in normal range of 4–11 KA units and 0 to 0.6 U/L
respectively in all groups of mice.
The activity of lactate dehydrogenase was found to be
maximum in infected mice treated with cisplatin followed by
infected untreated mice and uninfected untreated mice. When
antioxidants were supplemented along with cisplatin, the signifi-
cantly reduced levels of LDH were found on 1 p.t.d. as compared
to cisplatin treated mice and normal range of 114–240 IU/L was
observed on all post treatment days. When compared with SSG,
the results were found to be comparable (Fig. 7C).
Kidney function test
Treatment of infected and uninfected mice with cisplatin
(5 mg/kg bwt and 2.5 mg/kg bwt) led to a sudden increase in
the concentration of blood urea, BUN, uric acid and creatinine.
The increase was more pronounced in mice treated at the dosage
of 5 mg/kg b.wt. as compared to cisplatin at the dosage of
2.5 mg/kg b.wt. To reduce the nephrotoxicity induced by
cisplatin, antioxidants (vitamin C, vitamin E and silibinin) were
supplemented along with cisplatin. The levels of serum urea,
BUN, uric acid and creatinine were found to be within the normal
range of 10–45 mg/dl, 5–21 mg/dl, 3–6.7 mg/dl and 0.85–
1.35 mg/dl respectively in animals treated with cisplatin along
with antioxidants. The results were quite comparable to the SSG
treated mice where normal levels were found on different post
treatment days (Fig. 8A and 8B).
A significant decrease was found in electrolyte levels when
infected animals were treated with cisplatin and leads to
hyponatremia, hypomagnesemia, hypocalcemia, hypokalemia,
hypochloremia and hypophosphatemia. The decrease in electro-
Figure 5. Cytokine levels in culture supernatants of spleen cells of different groups of animals. A- IL-10, B- IL-4. The data are presented as
mean6S.D. of six mice per group. *,# -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m gC P +Silibinin/Infected+5m g
CP+VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. { -p value: Infected+5 mg CP vs. Infected+5m gC P +Silibinin/Infected+5m gC P +VitE+VitC/
Infected+5m gC P +VitE+VitC+Silibinin. *,{-p,0.001; #-p,0.05.
doi:10.1371/journal.pntd.0001629.g005
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cisplatin in comparison to those treated with 2.5 mg/kg b.wt. of
cisplatin. When the antioxidants were supplemented to reduce the
nephrotoxicity, the normal electrolyte levels were attained and the
serum sodium, potassium, phosphorus, chloride, calcium and
magnesium concentration was found to be within the range of 135
to 155 mmols/l, 3.6 to 5.5 mmols/l, 2.5–5 mg/dl, 98–109 mmols/
l, 8.7 to 10.5 mg/dl and 1.3 to 2.5 mg/dl respectively (Fig. 9A, 9B,
9C and Fig. 10A, 10B).
Mortality rate
The death rate was maximum in animals treated with cisplatin
(5 mg/kg bwt and 2.5 mg/kg bwt). This increased from 30–85%
and 25–75% in animals treated with cisplatin at the dosage of
5 mg/kg bwt. and 2.5 mg/kg bwt. on different post treatment
days. When antioxidants were given along with the drug in
infected animals, death rate was found to be 0%. The results were
found to be comparable to SSG treated animals where death rate
was found to be 0% on 30 p.t.d.
Discussion
The results of the present study demonstrated the antileishma-
nial efficacy of high doses of cisplatin. In addition treatment of L.
donovani infected animals with cisplatin along with antioxidants
(vitamin C, vitamin E and silibinin) ameliorated the nephrotoxicity
caused by administration of high dosage of cisplatin. The drug-
induced protective immune responses were associated with a
reduction in parasite burden as assessed by LDU in liver. It has
been observed that mice treated with higher dosage of cisplatin
(5 mg/kg b.wt.) showed better results by reducing the parasite load
by 97% as compared to low dosage (2.5 mg/kg b.wt.) which
proves its efficacy against the amastigote stage of L. donovani. These
findings correlate with the earlier studies from our laboratory
where the drug was found to be more effective at a concentration
of 1 mg/kg b.wt. as compared to 0.5 mg/kg b.wt. [10]. SSG at a
dosage of 40 mg/kg/day for 5 days intraperitoneally resulted in
reduction of parasite burden by 97% from liver. Similar
observations have been made by Trotter et al [22] who found
that 47 mg/kg/day of pentostam for 5 days cured 90% of
Figure 6. Total leucocyte count and hemoglobin levels in different groups of animals. A- Total Leukocyte Count, B- Hemoglobin levels.
The data are presented as mean6S.D. of six mice per group. *,# -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m g
CP+Silibinin/Infected+5m gC P +VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. {,1 -p value: Infected+5 mg CP vs. Infected+5m gC P +Silibinin/
Infected+5m gC P +VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. *,{-p,0.001; #,1-p,0.05.
doi:10.1371/journal.pntd.0001629.g006
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several previous studies which confirmed that SSG therapy cured
more than 95% of patients in Bihar [23]. In Pakistan, Nepal and
Sudan, cure rates in the range of 98%–100% have been reported
[24–26] The effectiveness of the newly developed antineoplastic
drug, cisplatin (cis-diamminedichloroplatinum II; CDDP) was
comparable with that of SSG as treatment with cisplatin resulted
in reduction of parasite load to a similar extent.
Our studies were in accordance with the findings of Geib et al
[27] where irinotecan/cisplatin treatment related deaths were
observed in 5 cases (19%), mainly due to infectious complications
due to excessive toxicity. Cisplatin should be used in combination
with antioxidants to overcome the side effects induced by cisplatin
and to increase the survival rate of animals. Our study has shown
that after antioxidant supplementation along with cisplatin, no
death was reported. Several cellular studies, animal and human
studies [28–31] have demonstrated that vitamins A, E, C, and K,
as well as beta-carotene and selenium—as single agents or in
combination—all protect against the toxicity of adriamycin and
actually enhance its cancer-killing effects and increase the survival
rate.
Delayed type hypersensitivity (DTH) is an immunologic
response that has been frequently used as a correlate for protection
against or sensitization to Leishmania antigen in humans and
Figure 7. SGOT, SGPT and LDH activity in serum samples of different groups of animals. A- SGOT, B-SGPT, C-LDH. The data are presented
as mean6S.D. of six mice per group.* -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m g C P +Silibinin/Infected+5m g
CP+VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. { -p value: Infected+5 mg CP vs. Infected+5m gC P +Silibinin/Infected+5m gC P +VitE+VitC/
Infected+5m gC P +VitE+VitC+Silibinin. *,{-p,0.001.
doi:10.1371/journal.pntd.0001629.g007
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demonstrate a positive correlation between enhanced DTH
responses and reduced parasite load demonstrating the generation
of Th1 type of protective immune responses [33] generated by
cisplatin. This response was found to be more pronounced in mice
treated with 5 mg/kg b.wt. as compared to those treated with
2.5 mg/kg b.wt. of cisplatin since maximum reduction in parasite
burden occurs after treatment with high dosage of cisplatin. We
have earlier reported increased DTH responses in cisplatin treated
animals, when two different doses (1 mg/kg b.wt. and 0.5 mg/kg
b.wt.) of cisplatin were tested. Higher dose revealed enhanced
DTH response as compared to a lower dose of cisplatin [10]. The
positive DTH response, which is an indicator of development of
cell-mediated immune responses, also develops after treatment
with the drug indicating thereby that this drug not only brought
about reduction in parasite load but also helped in regaining the
cell-mediated immune responses which is very important for
complete recovery. None of the two doses of the drug caused
depression of DTH response, thereby indicating that drug
treatment helped in reversal of immunosuppression caused by
the parasite.
Since, IgG2a and IgG1 kinetics indirectly reflect the Th1/Th2
responses, the relative production of these isotypes are used as a
marker for the induction of Th1-like and Th2-like immune
responses. The analysis of IgG isotypes disclosed a dichotomous
response to visceral infection. Treated animals produced low levels
of IgG and IgG1 in comparison to the infected controls but IgG2a
levels were reported to be slightly higher. A successful cure results
when levels of IgG2a increase with low levels of IgG1 in treated
groups driving the immune response towards Th1 type. The
results demonstrate a positive correlation of low IgG1 with high
cell mediated immune response, in terms of DTH and vice versa.
There is a correlation between the clinical outcome of the
infection and the cytokine response profile. Control of visceral
leishmaniasis in mice is believed to require IFN-c, produced by
spleen cells, which drives the immune response towards a Th1
phenotype by IL-2 [34]. To study the type of immune response
generated in the treated animals, the cytokine levels were
Figure 8. Blood urea and creatinine levels in serum samples of different groups of animals. A- Blood Urea, B- Creatinine. The data are
presented as mean6S.D. of six mice per group. * -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m g C P +Silibinin/
Infected+5m gC P +VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. {,1 -p value: Infected+5 mg CP vs. Infected+5m gC P +Silibinin/Infected+5m g
CP+VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. *,{-p,0.001; 1-p,0.05.
doi:10.1371/journal.pntd.0001629.g008
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Our results suggest that treatment with cisplatin preferentially
induces a type 1 immune response which resulted in significant
protection in mice against L. donovani infection. The infected and
cisplatin treated animals showed the maximum concentration of
Th1-specific cytokines, IFN-c and IL-2 and least concentration of
Th2-specific cytokines, IL-4 and IL-10 pointing towards the
potential of the drug to generate protective immune response
against L. donovani. High levels of IFN-c were also reported in the
patients exposed to whole cell extracts of the antigen [35].
Cisplatin (DDP) is one of the conventional anticancer agents
endowed with immunomodulating features [36]. When the dose of
cisplatin was increased to 5 mg/kg b.wt., all mice treated with this
dosage of drug showed increased production of Th1 specific
cytokines suggesting the generation of Th1 type of immune
response and the decrease in parasite load showed protective
nature of therapy. The increase was also found to be prominent at
low dosage (2.5 mg/kg b.wt.) but was lesser than at high dosage.
Cisplatin is known to boost the cytotoxic T-lymphocyte mediated
antitumor immunity [7,8]. Park et al [37] also showed that
cisplatin treatment increased the levels of IFN-c and IL-2. IL-10
has been suggested to play a role in counterbalancing the
Figure 9. Sodium, phosphate and chloride levels in serum samples of different groups of animals. A- Sodium, B- Phosphate, C- Chloride.
The data are presented as mean6S.D. of six mice per group.* -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m gC P +Silibinin/
Infected+5m gC P +VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. {,1 -p value: Infected+5 mg CP vs. Infected+5m gC P +Silibinin/Infected+5m g
CP+VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. *,{-p,0.001; 1-p,0.05.
doi:10.1371/journal.pntd.0001629.g009
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[38]. The studies of Lehman et al [39] confirmed that in visceral
leishmaniasis a Th1 dominated immune response is protective
against L. donovani parasites and furthermore, the capacity to
produce IFN-c rather than the presence of IL-4 determines the
efficacy of the immune response in susceptible miceHigh levels of
IL-4 and IL-10 in control animals supported a view that marked
up-regulation of these two cytokines is accompanied by suscepti-
bility, disease progression and depressed Th1 type of cell mediated
immunity with decreased production of IFN-c and IL-12 [40].
Our results confirmed these reports as progressive L. donovani
infection promote the production of IL-4 and IL-10 and at the
same time, suppressed the production of Th1 cytokines such as
IFN-c and IL-2. Similarly in humans, during active VL, the
immune response was predominantly of Th2 type, with the
absence of IFN-c in Leishmania antigen activated PBMC culture
supernatants [41]. So, treatment of mice with cisplatin significantly
brought down the IL-4 and IL-10 levels and enhanced the IFN-c
and IL-2 levels after therapy which points towards the shifting of
Th2 immune response to Th1 type of immune response, depicting
its protective role.
While toxicities induced by cisplatin include ototoxicity,
gastrotoxicity, myelosuppression, and allergic reactions [42,43]
the main dose-limiting side effect of cisplatin is nephrotoxicity
[44,45]. Nephrotoxicity increases with the dose and frequency of
administration and cumulative dose of cisplatin [44]. As cisplatin
causes nephrotoxicity, it has been suggested that the toxic effects of
cisplatin may be related to free radical induced damage which can
be reduced by the supplementation of antioxidants [46] leading to
the possibility that cisplatin may be used in combination with
antioxidants which might suppress the drug-induced toxic effects.
To assess the drug induced side effects, various haematological
and biochemical studies were carried out. Regarding the
hematological parameters, anemia is a frequent manifestation of
visceral leishmaniasis that appear with the disease after an
incubation period ranging from one month to several years [47]
which is in accordance with our study where anemia was found in
mice infected with L. donovani. Cisplatin treatment at both dosages
brought about a significant reduction in the white blood cells and
anemia. This is in accordance with an earlier study by Khynriam
and Prasad [21] where cisplatin treatment of tumor bearing mice
caused a decrease in total leucocytes and severe anemia when
Figure 10. Calcium and magnesium levels in serum samples of different groups of animals. A- Calcium, B- Magnesium. The data are
presented as mean6S.D. of six mice per group. * -p value: Infected only vs Infected+SSG/Infected+5 mg CP/Infected+5m g C P +Silibinin/
Infected+5m gC P +VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. {,1 -p value: Infected+5 mg CP vs. Infected+5m gC P +Silibinin/Infected+5m g
CP+VitE+VitC/Infected+5m gC P +VitE+VitC+Silibinin. *,{-p,0.001; 1-p,0.05.
doi:10.1371/journal.pntd.0001629.g010
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studies of Nair et al [48] where body weight, hemoglobin levels
and leucocyte counts were decreased after cisplatin injection in
mice. In a previous study, a reduction in ototoxicity, renal toxicity,
and hematologic toxicity in animals treated with cisplatin plus
supplementation with high doses of antioxidants [46] has been
reported which is further correlated with our findings where
antioxidant supplementation showed no discrepancy in the
hematological parameters.
Liver enzymes are the earliest to show a rise even before the
appearance of clinical signs (hepatic damage, pulmonary tuber-
culosis) and their monitoring at various intervals is thus an index of
the extent of damage to the liver [49]. It has already been observed
that all the medications used to treat visceral leishmaniasis may be
associated with significant increase in levels of liver enzymes
during treatment which may be due to the killing of the parasites
in liver, rather than to direct medication induced hepatotoxic
effects [50] and thus hepatocyte damage is considered as a non-
desirable side effect [51]. Infected animals treated with cisplatin at
the dose of 5 mg/kg b.wt. and 2.5 mg/kg b.wt. showed increase in
SGOT, SGPT and LDH levels depicting hepatocellular damage.
Hepatotoxicty is a rare side effect of cisplatin. However, it is
known that cisplatin is significantly taken up in human liver [52].
Some reports suggest that cisplatin-induced hepatotoxicity may be
dose-related [52]. High doses of cisplatin have been found to
produce hepatotoxicity, with apoptosis as the major lesion, and
metallothionein protects against cisplatin-induced liver injury [53].
Our study has shown pronounced increase in liver enzymes in
mice treated with high dosage as compared to those treated with
low dosage. The increase in hepatic enzymes is more pronounced
in infected and treated animals which may be because the parasite
causes structural and functional derangement of liver. Zicca et al
[52] showed that the high dose of cisplatin (7.5 mg/kg)
administered to rats caused an evident liver damage characterized
by significant increase of glutamic oxaloacetic transaminase and
c–glutamyl transpeptidase plasma activities [52]. Furthermore,
Lactate dehydrogenase (LDH) enzyme is considered to be a
specific marker for tissue damage [54]. LDH is a key enzyme in
energy metabolism located in the cell cytoplasm and alkaline
phosphatase is a phosphohydrolase enzyme attached to the cell
wall by glycosyl phosphatidyl inositol anchors. Activities of these
enzymes in urine are physiologically very low. Therefore, any
increase in their activities suggests proximal tubular cell damage
[55]. Cisplatin treatment at both the dosages brought about
increase in LDH level which is related to the studies of Sudhakar
et al. [56] where cisplatin treatment significantly increased the
enzyme activities of SGOT, SGPT and LDH levels. It has been
established that lipid peroxidation might participate in the
hepatotoxicity in cisplatin-treated animals despite activation of
antioxidant enzymes [57]. It has been suggested that antioxidant
enzymes represent the protective response against cisplatin toxicity
in the livers of tumor-bearing animals [53]. Many antioxidants
have been studied to protect tissue from cisplatin’s side effects. In
the present study, administration of antioxidants reduced the side
effects causing the hepatocellular damage by cisplatin administra-
tion. This could be substantiated with the observation of Molander
et al. [58], who have also reported that the serum levels of the
transaminases return to normal as the liver parenchyma heals and
the liver cells regenerates. Silibinin is the most biologically active
component with regard to antioxidant and hepatoprotective
properties [59]. Pretreating rats and mice with silymarin before
exposure to chemical hepatotoxins, such as carbon tetrachloride,
thallium, acetaminophen and halothane, significantly reduced
lipid peroxidation and hepatotoxicity [60] which is consistent with
our study where silibinin administration showed protective
response against hepatic damage. Recent work by Seo and Lee
[61] provides evidence that low vitamin C intake as ascorbic acid
acts primarily as an antioxidant and prevents hepatotoxicity. Both
the findings are correlated to our study where supplementation of
a-tocopherol and ascorbic acid showed the antioxidant effect and
reduced the hepatotoxicity which might be caused by the killing of
the parasite or by the administration of cisplatin. SSG treatment
brought about a transient increase in SGOT and SGPT which
returned to their normal levels within 15 to 30 p.t.d., thereby
indicating that drug treatment may cause reversal of damage
caused by the parasite and shows recovery of the damaged liver. It
may be possible that liver finds it difficult to deal with the load of
the drug and parasite but after increase in post treatment days, it
may be capable of recovery. Our results clearly support the
findings of Crofton and Andrews [62] that liver enzymes improved
as patients progressed under chemotherapy.
Cisplatin has been shown to cause nephrotoxicity in patients
[63] as well as in a variety of animal species [64]. On studying the
renal parameters, increase in levels of serum urea, BUN, uric acid,
creatinine and decrease in electrolytes like Mg, Na etc. was
observed in the cisplatin (both doses) treated animals. The increase
in renal parameters after cisplatin treatment points towards the
nephrotoxic effect of the drug. The findings correlate with earlier
studies of some workers where a marked increase in blood urea
nitrogen and creatinine in serum on treatment with cisplatin at
different doses has been reported [65]. The increase of serum
creatinine and urea levels was 7 and 5.7-fold, respectively after
treatment with cisplatin at a dosage of 16 mg/kg b.wt. [66]. Kaur
et al [10] also reported an increase in the renal parameters of mice
on cisplatin administration. In our study, loss of electrolytes has
been observed, resulting in hyponatremia, hypomagnesemia,
hypocalcemia, hypokalemia and hypophosphatemia when infected
mice were treated with cisplatin. This decrease was more transient
with high dose of cisplatin (5 mg/kg b.wt.). Cisplatin (CDDP) is a
well-known chemotherapeutic agent that is associated with
hyponatremia. Cisplatin regimens can lead to a more or less
pronounced hyponatremia in 4 to 10% of cases due to salt wasting
with hypomagnesemia and normokalemia [67]. This is in
accordance with our study where cisplatin administration caused
hyponatremia in Leismania donovani infected mice. However, in
relevance to our study moderate hyponatremia (131 mmol/l)
without any other biological or clinical disturbances was noticed
on day 6 of cisplatin administration in the studies by el Weshi et al.
[67].
Hypomagnesemia is a well-known side-effect in patients
undergoing chemotherapy with cisplatin containing regimens
and very little is actually known about the clinical importance of
hypomagnesemia as induced by cisplatin. When cisplatin induces
renal injury, declining values of serum magnesium seem to be one
of the earliest signs and can be found in the presence of otherwise
normal tubular function [68]. Ariceta et al. [69] found, that the
minimal cumulative dose required to induce hypomagnesemia was
300 mg/m
2 of cisplatin. Buckley et al. [70] followed 50 patients
receiving cisplatin in doses of 50 mg/m
2 at four weeks intervals.
They found that the incidence of hypomagnesemia increased
during treatment from 41% after one course of chemotherapy to
100% in patients receiving six courses of chemotherapy [71] Our
results are in accordance to a previous study where administration
of cisplatin to dogs resulted in an increase in potassium clearance
[72] which leads to hypokalemia. This might result from the
proximal tubular injury by cisplatin leading to an increased
delivery of sodium, potassium and water to the distal nephron,
which creates a sodium-load dependent potassium secretion.
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in and the actual frequency is probably dependent on the
administered dose. Correction of magnesium blood levels usually
should improve the hypocalcemia [73]. Although, mild hypocal-
cemia is reported in high dose cisplatin treatment, severe
hypocalcemia has not been reported in low dose cisplatin
treatment [74] as in our previous study where administration of
cisplatin at low dosage caused no change in calcium levels [10].
Cisplatin induced suppression of renal antioxidant enzyme
activity in previous studies [75,76] suggests that the diminution of
these renal antioxidant systems caused by the drug can be
prevented by the supplementation with antioxidants. The balance
between oxidant and antioxidant system seemed to be disturbed in
our study due to cisplatin administration, and to obviate
impairment of this balance supplementation of antioxidants prior
to administration of cisplatin is required. Cisplatin induced
suppression of renal antioxidant enzyme activities has also
supported by Ajith et al [75] and Cetin et al [76]. The present
study suggested that administration of antioxidants (vitamin C,
vitamin E and Silibinin) before cisplatin injection causes the
reversal of renal damage. A higher dose of cisplatin was selected in
the study to explore the protective effect of the antioxidants when
cisplatin caused maximum damage to the kidneys. We found that
vitamin C, vitamin E and flavonoid (silibinin) significantly
sheltered the cisplatin-induced nephrotoxicity by impairing the
antioxidant system. In the study by Weijl et al [77], cancer patients
received cisplatin-based chemotherapy, in which half the patients
were given a dietary supplement that consisted of vitamin C,
vitamin E and selenium. These patients showed recovery with
respect to the severity of the nephrotoxicity induced by cisplatin. It
has also been shown that both vitamins E and C decreased lipid
peroxidation and augmented the activity of antioxidant enzymes
in the kidneys of diabetic rats [78]. In another study, lipid peroxide
levels were reduced and levels of antioxidant enzymes and thiol
compounds were increased following administration of a-tocoph-
erol and ascorbic acid in lead-induced oxidative stress [79] It has
been reported that administration of cisplatin at the dosage of
6 mg/kg b.wt., intraperitoneally, at an interval of 120 hours,
resulted in a significant increase in the concentration of blood urea
nitrogen and creatinine. However, when vitamin E and cysteine
were administered along with the cisplatin, the results were
partially reversed [65], which supports our findings where normal
range of blood urea nitrogen, urea and creatinine levels after the
administration of cisplatin (5 mg/kg b.wt. and 2.5 mg/kg b.wt.)
along with different antioxidants were reported. Our results were
also in accordance with the studies of Ajith et al [80] and
Appenroth et al [17] where significant reduction in various liver
and kidney function tests was reported when both vitamin C and
vitamin E were administered together. Silibinin possesses anti-
oxidant and membrane-stabilizing properties that have already
been elucidated in hepatocytes challenged with a variety of
radical-generating drugs [81]. Silibinin partly or totally amelio-
rated cisplatin induced alterations in parameters associated with
proximal tubular function. Administration of cisplatin caused a
decline in kidney function within a day following treatment but
administration of silibinin caused the reversal of kidney function
tests within normal range. Our results were in accordance with the
studies of Gaedeke et al [15] where similar results were evaluated.
Hypomagnesemia observed by Mavichak et al. [82] was also
reported from our study after cisplatin treatment but not after
treatment with cisplatin in combination with silibinin signifying its
strong antioxidant potential. However, silymarin caused a marked
decrease in potassium excretion, suggesting that this constituent is
a potassium-sparing diuretic [83]. The above findings correlates
with our study where silibinin in combination with vitamins and
even alone ameliorated the cisplatin induced alterations in the
kidney function tests. Concomitant treatment of antioxidants
rendered protection from oxidants attack. All the enzymatic levels
which were reported to be higher in the infected controls and the
infected plus cisplatin treated animals, ended up being normal in
the animals treated with cisplatin and vitamin C, vitamin E and
silibinin combination.
Hence, we establish that higher dosage of cisplatin is effective in
diminution of parasite burden in visceral leishmaniasis. However,
it is recommended that higher dose should be used in combination
with antioxidants which help in suppression of drug-induced toxic
effects. The results presented in the study are promising in context
of reduction in parasite burden, enhancement of immune
responses and reduction in the toxic effects. The encouraging
results could lead to studies with combination of immunomodu-
lators/herbal extracts and in other animal models for further
development of cisplatin as an antileishmanial therapy. To
examine the immunomodulatory effect of cisplatin, further studies
can be carried in immunosuppressed models.
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